A ntimicrobial resistance (AMR) in Neisseria gonorrhoeae, the causative agent of the disease gonorrhea, is a major public issue and is now recognized by the U.S. Centers for Disease Control and Prevention (CDC) as one of the top three urgent AMR threats (1). Action plans to control the impact and spread of N. gonorrhoeae AMR have been released by the World Health Organization (WHO) and CDC (2, 3), and prominent among the listed recommendations is the need to improve AMR surveillance capabilities. Conventional N. gonorrhoeae AMR surveillance is performed by bacterial culture. However, bacterial culture has several major limitations, including the need for stringent sample handling and transport systems to maintain viable organisms, which are problems in remote and resource-limited settings. In addition, nucleic acid amplification tests (NAATs) are increasingly commonplace in the diagnosis of gonococcal infections in both remote and urban settings, which in turn are seeing further reductions in the use of bacterial culture and widening gaps in AMR data. For these reasons, there has been an increasing need for the development of molecular methods to enhance AMR surveillance activity (4). We recently described a real-time PCR method to detect penicillinase-producing N. gonorrhoeae (PPNG) directly within clinical samples (5). The method acts as an indirect marker for PPNG by targeting a region of DNA on the gonococcal plasmids carrying the penicillinase gene but not the penicillinase gene itself. The original evaluations of this PPNG-PCR showed 100% sensitivity and 98.7% specificity compared to bacterial culture for detecting PPNG strains in clinical specimens (5). However, a more recent evaluation of the assay revealed a variant plasmid type, now called the Australian plasmid, which was negative by . In brief, we tested 342 PPNG isolates from throughout Australia from the year 2012 and found one isolate that was negative by PPNG-PCR. DNA sequencing revealed a novel 1,885-bp deletion (corresponding to nucleotides 502 to 2385 of the Asian plasmid type, GenBank accession no. U20374), which included the region targeted by the PPNG-PCR (937 to 1024 bp) and hence accounted for the false-negative result. Several different gonococcal plasmids with various different deletions and insertions have now been described and named according to the geographical location of their initial discovery; these include the Asian (7,426 bp), African (5,599 bp), Rio de Janeiro/Toronto (5,154 bp), Nimes (6,798 bp), New Zealand (9,309 bp), Johannesburg (4,865 bp), and now the Australian (3,629 bp) plasmids (6-8).
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While our initial data suggest that the Australian plasmid may be rare in local gonococci, we sought to rectify the PPNG-PCR to account for this plasmid, particularly given that the PPNG-PCR is now used as a routine tool to inform gonorrhea treatment guidelines in remote parts of Australia where penicillin-based treatments are still used (9) . In doing so, we aimed to limit the potential for false-negative results caused by further unrecognized deletions or insertions by adopting a multitarget approach. To this effect, the modified PPNG-PCR method (PPNG-triplex-PCR) is a multiplex PCR method and comprises the original PPNG-PCR oligonucleotides (PPNG target 1, Table 1 ), a second set of newly designed PPNG oligonucleotides (PPNG target 2, Table 1 ), and oligonucleotides targeting the gonococcal opa genes to serve as an internal control (opa gene target, Table 1 ). The new PPNG target 2 oligonucleotides target a different region from that of the original PPNG-PCR method (corresponding to nucleotides 6160 to 6313 of the Asian plasmid type, GenBank accession no. U20374). This particular region, which flanks the start of transposon Tn2 (nucleotide 6235; GenBank accession no. U20374), was predicted to be conserved across all recognized gonococcal plasmid types based on previous descriptions of these plasmids (6-8) and anal-ysis of available sequences from the GenBank database. The opabased internal control PCR was included to show that amplifiable gonococcal DNA was present when testing nucleic acids extracted from clinical samples.
The PPNG-triplex-PCR assay consisted of 10.0 l of QuantiTect probe PCR master mix (Qiagen, Doncaster, Australia), 0.125 M PPNG target 1 primers (PPNG-t1-F and PPNG-t1-2, Table  1 ), 0.5 M PPNG target 2 primers (PPNG-t2-F and PPNG-t2-2, Table 1 ), 0.25 M opa gene primers (GCopa-F and GCopa-R, Table 1 ), 0.2 M each probe (PPNG-t1-probe, PPNG-t2-probe, and GCopa-Probe, Table 1 ), and 2.0 l of sample extract or isolate DNA and was made up to 20.0 l using DNase-free water. The differing primer concentrations were used to limit competition between the three targets (data not shown). Real-time PCR was carried out using the Rotor-Gene Q and Rotor-Gene 6000 instruments (Qiagen), with the following cycling parameters: hold at 95°C for 15 min, followed by 45 cycles at 95°C for 15 s and then 60°C for 60 s. Only samples providing cycle threshold (C T ) values of Ͻ35 cycles by either of the PPNG-PCR methods were considered to be true PPNG positives, as previously described (5) .
The PPNG-triplex-PCR assay was initially evaluated by retesting the above-mentioned 342 Australian PPNG isolates, which included representatives of the Asian, African, and Rio de Janeiro/ Toronto plasmids in addition to the Australian plasmid. All isolates provided positive results in both PPNG targets, with the exception of the isolate harboring the Australian variant, which was positive by PPNG target 2 and, as expected, was negative by the PPNG target 1 PCR. To examine clinical performance, the PPNGtriplex-PCR was then applied to DNA extracts of 415 clinical samples (Table 2) , providing positive results for N. gonorrhoeae by the Versant CT/GC DNA NAAT (Siemens Healthcare Diagnostics) and by supplemental in-house PCR methods. These 415 samples comprised 94 vaginal (22.7% of samples), 40 urethral (9.6%), 29 cervical (7.0%), 14 throat (3.4%), 11 anal/rectal (2.7%), 2 penile swabs (0.5%), and 1 eye swab (0.2%) samples, as well as 198 urine samples (47.7%), 6 joint fluid samples (1.4%), and 20 samples (4.8%) for which the site was not specified. The extracts were kindly provided by the Royal Darwin Hospital Laboratory, Northern Territory, and comprised all available N. gonorrhoeae NAATpositive samples tested by the hospital in the first half of 2014. Based on the gonorrheal notification data, these were estimated to comprise approximately 35% of all notified gonorrhea cases in the Northern Territory during this period. A subset of these samples (n ϭ 193) also had corresponding bacterial culture results. Of these, 85 were negative by culture (i.e., no gonococci were isolated), 96 were penicillin ␤-lactamase negative, and the remaining 12 were identified as PPNG via phenotypic methods. The low yield of culture reflects the challenges of transporting clinical samples across great distances in the Northern Territory.
The results of the PPNG-triplex-PCR testing for the 415 samples are summarized in Table 2 . In brief, 21 (5.1%) samples were PPNG positive, and 311 (74.9%) were non-PPNG by the PPNGtriplex-PCR method. A further 83 (20%) samples were negative by both PPNG-PCR methods and the opa internal control PCR and were considered to be no-call results by the PPNG-triplex-PCR. Compared to the available culture results, the PPNG-triplex-PCR assay successfully identified 11 of 12 samples that were PPNG positive by culture (sensitivity, 91.7%; 95% confidence interval [CI], 64.6% to 98.5%) and gave complete agreement for the non-PPNG samples (84/84 samples; specificity, 100%; 95% CI, 95.6% to 100%). However, the PPNG-triplex-PCR assay missed one sample that was recorded as PPNG positive by culture. This sample provided a C T value of 30 cycles in the opa gene PCR, indicating that a moderate load of amplifiable gonococcal DNA was present. At such a load, we would have expected the PPNG-PCR assays to have readily amplified their plasmid targets. The isolate from this sample was not available for repeat testing. Additional testing was carried out on the sample using a previously described multiplex PCR to differentiate ␤-lactamase plasmids of N. gonorrhoeae (7), and negative results were again obtained (data not shown). We therefore do not believe this reflects a false-negative result by the PPNG-triplex-PCR assay but rather is suggestive of a sample mixup or data entry error.
Overall, the results show that the PPNG-triplex-PCR is suitable for routine detection of PPNG strains directly in clinical samples so as to enhance bacterial culture-based surveillance. Moreover, its multitarget approach limits the potential for sequence variation to cause false-negative results.
